Daisuke Aoki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6987372/publications.pdf Version: 2024-02-01



DAISLIKE AOKI

#	Article	IF	CITATIONS
1	Abdominal radical trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer in a series of 61 women. Gynecologic Oncology, 2009, 115, 51-55.	1.4	121
2	Clinical statistics of gynecologic cancers in Japan. Journal of Gynecologic Oncology, 2017, 28, e32.	2.2	120
3	MicroRNA in Cervical Cancer: OncomiRs and Tumor Suppressor miRs in Diagnosis and Treatment. Scientific World Journal, The, 2014, 2014, 1-8.	2.1	118
4	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. Journal of Clinical Oncology, 2016, 34, 2881-2887.	1.6	114
5	Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. International Journal of Clinical Oncology, 2019, 24, 1-19.	2.2	106
6	Carcinogenic mechanisms of endometrial cancer: Involvement of genetics and epigenetics. Journal of Obstetrics and Gynaecology Research, 2014, 40, 1957-1967.	1.3	89
7	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of Clinical Oncology, 2021, 39, 3671-3681.	1.6	84
8	Uterine autotransplantation in cynomolgus macaques: the first case of pregnancy and delivery. Human Reproduction, 2012, 27, 2332-2340.	0.9	83
9	The first Japanese nationwide multicenter study of <i>BRCA</i> mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of <i>BRCA</i> (CHARLOTTE). International Journal of Gynecological Cancer, 2019, 29, 1043-1049.	2.5	80
10	Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. British Journal of Cancer, 2017, 117, 717-724.	6.4	78
11	A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. Gynecologic Oncology, 2017, 144, 384-390.	1.4	77
12	Realâ€world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Science, 2021, 112, 1105-1113.	3.9	73
13	The Japanese Guideline for Cervical Cancer Screening. Japanese Journal of Clinical Oncology, 2010, 40, 485-502.	1.3	65
14	Features of ovarian cancer in Lynch syndrome (Review). Molecular and Clinical Oncology, 2014, 2, 909-916.	1.0	63
15	Application of MicroRNA in Diagnosis and Treatment of Ovarian Cancer. BioMed Research International, 2014, 2014, 1-6.	1.9	60
16	Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. Journal of Gynecologic Oncology, 2020, 31, e18.	2.2	59
17	Overexpression of Class III β-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma. Clinical Cancer Research, 2009, 15, 1473-1480.	7.0	57
18	Current status of uterus transplantation in primates and issues for clinical application. Fertility and Sterility, 2013, 100, 280-294.	1.0	52

#	Article	IF	CITATIONS
19	Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. International Journal of Clinical Oncology, 2010, 15, 117-124.	2.2	51
20	A new surgical technique of uterine auto-transplantation in cynomolgus monkey: preliminary report about two cases. Archives of Gynecology and Obstetrics, 2012, 285, 129-137.	1.7	49
21	Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget, 2017, 8, 72147-72156.	1.8	49
22	Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget, 2017, 8, 112258-112267.	1.8	49
23	Uterus allotransplantation in cynomolgus macaque: A preliminary experience with nonâ€human primate models. Journal of Obstetrics and Gynaecology Research, 2014, 40, 907-918.	1.3	48
24	Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome. International Journal of Oncology, 2012, 41, 793-797.	3.3	46
25	Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?. Journal of Gynecologic Oncology, 2018, 29, e21.	2.2	46
26	Uterus autotransplantation in cynomolgus macaques: intraoperative evaluation of uterine blood flow using indocyanine green. Human Reproduction, 2011, 26, 3019-3027.	0.9	45
27	Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reproductive Biology and Endocrinology, 2016, 14, 2.	3.3	45
28	Glutaminolysisâ€related genes determine sensitivity to xCTâ€ŧargeted therapy in head and neck squamous cell carcinoma. Cancer Science, 2019, 110, 3453-3463.	3.9	45
29	Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. International Journal of Clinical Oncology, 2010, 15, 531-542.	2.2	44
30	High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. Acta Histochemica Et Cytochemica, 2014, 47, 295-301.	1.6	44
31	Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013. Journal of Obstetrics and Gynaecology Research, 2014, 40, 338-348.	1.3	42
32	High Expression of p62 Protein Is Associated with Poor Prognosis and Aggressive Phenotypes in Endometrial Cancer. American Journal of Pathology, 2015, 185, 2523-2533.	3.8	42
33	Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer. Carcinogenesis, 2019, 40, 611-623.	2.8	42
34	Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncology Reports, 2006, 16, 1189-96.	2.6	42
35	Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer. International Journal of Oncology, 2015, 46, 1498-1506.	3.3	41
36	Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer, 1997, 79, 169-176.	4.1	38

#	Article	IF	CITATIONS
37	Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group, Japanese Journal of Clinical Oncology, 2008, 38, 777-785.	1.3	37
38	Indocyanine Green Fluorescence Imaging for Evaluation of Uterine Blood Flow in Cynomolgus Macaque. PLoS ONE, 2012, 7, e35124.	2.5	37
39	Clinicopathologic Analysis With Immunohistochemistry for DNA Mismatch Repair Protein Expression in Synchronous Primary Endometrial and Ovarian Cancers. International Journal of Gynecological Cancer, 2015, 25, 440-446.	2.5	37
40	Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics, 2012, 4, 147-162.	2.1	36
41	The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer: clinical and pathological factors influencing it. Japanese Journal of Clinical Oncology, 2015, 45, 26-34.	1.3	34
42	Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology. Journal of Obstetrics and Gynaecology Research, 2015, 41, 1861-1869.	1.3	33
43	A surgical technique using the ovarian vein in nonâ€human primate models of potential livingâ€donor surgery of uterus transplantation. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 942-948.	2.8	31
44	Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. British Journal of Cancer, 2015, 113, 1477-1483.	6.4	30
45	Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning. Oncology Letters, 2016, 11, 1287-1293.	1.8	29
46	Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer. Scientific World Journal, The, 2015, 2015, 1-10.	2.1	28
47	Evaluation of allowable time and histopathological changes in warm ischemia of the uterus in cynomolgus monkey as a model for uterus transplantation. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 991-998.	2.8	28
48	Current state and outlook for drug repositioning anticipated in the field of ovarian cancer. Journal of Gynecologic Oncology, 2019, 30, e10.	2.2	28
49	Survey of Attitudes toward Uterus Transplantation among Japanese Women of Reproductive Age: A Cross-Sectional Study. PLoS ONE, 2016, 11, e0156179.	2.5	27
50	Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTEâ€100. Cancer Science, 2020, 111, 1324-1332.	3.9	27
51	Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review). Molecular and Clinical Oncology, 2014, 2, 647-655.	1.0	26
52	The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Journal of Gynecologic Oncology, 2021, 32, e49.	2.2	26
53	Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. Biomedical Reports, 2013, 1, 335-340.	2.0	25
54	Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by Epigenetics. Biochemistry Research International, 2012, 2012, 1-5.	3.3	24

#	Article	IF	CITATIONS
55	Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology. Journal of Obstetrics and Gynaecology Research, 2015, 41, 167-177.	1.3	23
56	Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy. Gynecologic Oncology, 2020, 159, 329-334.	1.4	23
57	Clinical implications of nextâ€generation sequencingâ€based panel tests for malignant ovarian tumors. Cancer Medicine, 2020, 9, 7407-7417.	2.8	23
58	Identification of germline MSH2 gene mutations in endometrial cancer not fulfilling the new clinical criteria for hereditary nonpolyposis colorectal cancer. Cancer Genetics and Cytogenetics, 2003, 146, 58-65.	1.0	21
59	Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncology Reports, 2006, 16, 1189.	2.6	21
60	Surgical technique for allogeneic uterus transplantation in macaques. Scientific Reports, 2016, 6, 35989.	3.3	21
61	Allowable warm ischemic time and morphological and biochemical changes in uterine ischemia/reperfusion injury in cynomolgus macaque: a basic study for uterus transplantation. Human Reproduction, 2017, 32, 2026-2035.	0.9	21
62	Warburg effect in Gynecologic cancers. Journal of Obstetrics and Gynaecology Research, 2019, 45, 542-548.	1.3	20
63	Relationship of lower uterine segment cancer with Lynch syndrome: A novel case with an hMLH1 germline mutation. Oncology Reports, 2012, 28, 1537-1543.	2.6	19
64	Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis. Journal of Gynecologic Oncology, 2020, 31, e67.	2.2	19
65	Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients. Journal of Human Genetics, 2013, 58, 794-798.	2.3	18
66	Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer. Journal of Gynecologic Oncology, 2018, 29, e23.	2.2	18
67	Current status of molecular-targeted drugs for endometrial cancer (Review). Molecular and Clinical Oncology, 2013, 1, 799-804.	1.0	17
68	Current Progress in Uterus Transplantation Research in Asia. Journal of Clinical Medicine, 2019, 8, 245.	2.4	17
69	Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer. Molecular Biology International, 2011, 2011, 1-6.	1.7	17
70	Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future. Japanese Journal of Clinical Oncology, 2013, 43, 515-519.	1.3	16
71	Current status of cancer immunotherapy for gynecologic malignancies. Japanese Journal of Clinical Oncology, 2021, 51, 167-172.	1.3	16
72	ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer. Gynecologic Oncology, 2021, 162, 679-685.	1.4	16

#	Article	IF	CITATIONS
73	Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3). Japanese Journal of Clinical Oncology, 2017, 47, 986-990.	1.3	15
74	Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab. Journal of Obstetrics and Gynaecology Research, 2020, 46, 190-195.	1.3	15
75	Establishment and Characterization of the RMG-V Cell Line from Human Ovarian Clear Cell Adenocarcinoma. Human Cell, 2005, 18, 143-146.	2.7	14
76	Basic research on uterus transplantation in nonhuman primates in Japan. Journal of Obstetrics and Gynaecology Research, 2018, 44, 1871-1881.	1.3	14
77	Glycan profiling of gestational choriocarcinoma using a lectin microarray. Oncology Reports, 2014, 31, 1121-1126.	2.6	13
78	Intermittent pneumatic compression for prevention of pulmonary thromboembolism after gynecologic surgery. Thrombosis Journal, 2005, 3, 18.	2.1	12
79	Family History and BRCA1/BRCA2 Status Among Japanese Ovarian Cancer Patients and Occult Cancer in a BRCA1 Mutant Case. Japanese Journal of Clinical Oncology, 2014, 44, 49-56.	1.3	12
80	CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women. Cancer Epidemiology, 2017, 50, 60-67.	1.9	12
81	Liquid-based cytology versus conventional cytology for detection of uterine cervical lesions: a prospective observational study. Japanese Journal of Clinical Oncology, 2018, 48, 522-528.	1.3	12
82	Indocyanine green fluorescence imaging in the pregnant cynomolgus macaque: childbearing is supported by a unilateral uterine artery and vein alone?. Archives of Gynecology and Obstetrics, 2013, 288, 1309-1315.	1.7	11
83	A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma. Molecular and Clinical Oncology, 2014, 2, 591-595.	1.0	11
84	Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer. Journal of Gynecologic Oncology, 2018, 29, e29.	2.2	11
85	Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?. European Journal of Cancer Prevention, 2019, 28, 562-567.	1.3	11
86	Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter. Gynecologic Oncology, 2019, 155, 340-348.	1.4	11
87	Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project. Gynecologic Oncology, 2020, 159, 248-255.	1.4	11
88	Ovarian Cancer. BioMed Research International, 2014, 2014, 1-2.	1.9	10
89	A Comparison of Dye Versus Fluorescence Methods for Sentinel Lymph Node Mapping in Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 1517-1524.	2.5	10
90	Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea. Journal of Gynecologic Oncology, 2020, 31, e65.	2.2	10

#	Article	IF	CITATIONS
91	A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer. Japanese Journal of Clinical Oncology, 2015, 45, 422-426.	1.3	9
92	Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience. Journal of Ovarian Research, 2020, 13, 105.	3.0	9
93	Lymphadenectomy issues in endometrial cancer. Journal of Gynecologic Oncology, 2021, 32, e25.	2.2	9
94	Operative and Clinical Outcomes of Minimally Invasive Living-Donor Surgery on Uterus Transplantation: A Literature Review. Journal of Clinical Medicine, 2021, 10, 349.	2.4	9
95	How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey. International Journal of Clinical Oncology, 2015, 20, 997-1004.	2.2	8
96	Methylation Analysis of DNA Mismatch Repair Genes Using DNA Derived from the Peripheral Blood of Patients with Endometrial Cancer: Epimutation in Endometrial Carcinogenesis. Genes, 2016, 7, 86.	2.4	8
97	Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines. Glycoconjugate Journal, 2016, 33, 745-754.	2.7	8
98	Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer. Molecular and Clinical Oncology, 2015, 3, 267-273.	1.0	7
99	Differential micro ribonucleic acid expression profiling in ovarian endometrioma with leuprolide acetate treatment. Journal of Obstetrics and Gynaecology Research, 2016, 42, 1734-1743.	1.3	7
100	First Successful Delivery after Uterus Transplantation in MHC-Defined Cynomolgus Macaques. Journal of Clinical Medicine, 2020, 9, 3694.	2.4	7
101	The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee. Journal of Gynecologic Oncology, 2021, 32, e44.	2.2	7
102	A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma and clear cell carcinoma. Journal of <u>Gynecologic Oncology</u> , 2020, 31, e45.	2.2	7
103	<i>TP53</i> variants in p53 signatures and the clonality of STICs in RRSO samples. Journal of Gynecologic Oncology, 2022, 33, .	2.2	7
104	Current status and future directions of ovarian cancer prognostic models. Journal of Gynecologic Oncology, 2021, 32, e34.	2.2	6
105	The first-round results of a population-based cohort study of HPV testing in Japanese cervical cancer screening: baseline characteristics, screening results, and referral rate. Journal of Gynecologic Oncology, 2021, 32, e29.	2.2	6
106	Efficacy of 18-FDG PET-CT dual-phase scanning for detection of lymph node metastasis in gynecological cancer. Anticancer Research, 2015, 35, 2247-53.	1.1	6
107	A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma. Japanese Journal of Clinical Oncology, 2011, 41, 320-327.	1.3	5
108	Repair of congenital 'disconnected uterus': a new female genital anomaly?. Human Reproduction, 2015, 30, 46-48.	0.9	5

#	Article	IF	CITATIONS
109	Comparison of methods using paraffinâ€embedded tissues and exfoliated cervical cells to evaluate human papillomavirus genotype attribution. Cancer Science, 2016, 107, 1520-1526.	3.9	5
110	Synchronous endometrial and ovarian cancer in Lynch syndrome with a MSH2 germline mutation: A case report. Molecular and Clinical Oncology, 2018, 9, 479-484.	1.0	5
111	Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells. Human Cell, 2019, 32, 447-452.	2.7	5
112	Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution. Japanese Journal of Clinical Oncology, 2021, 51, 213-217.	1.3	5
113	Impact of lymphadenectomy on the treatment of endometrial cancer using data from the JSOG cancer registry. Obstetrics and Gynecology Science, 2021, 64, 80-89.	1.6	5
114	Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study. International Journal of Clinical Oncology, 2021, 26, 971-979.	2.2	5
115	Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. Anticancer Research, 2009, 29, 561-6.	1.1	5
116	Osteoporosis is less frequent in endometrial cancer survivors with hypertriglyceridemia. Japanese Journal of Clinical Oncology, 2015, 45, 127-131.	1.3	4
117	Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer. Japanese Journal of Clinical Oncology, 2017, 47, 401-406.	1.3	4
118	Hysteroscopic Photodynamic Diagnosis Using 5-Aminolevulinic Acid: A High-Sensitivity Diagnostic Method for Uterine Endometrial Malignant Diseases. Journal of Minimally Invasive Gynecology, 2020, 27, 1087-1094.	0.6	4
119	Spermatogenesis-associated changes of fucosylated glycolipids in murine testis. Human Cell, 2020, 33, 23-28.	2.7	4
120	Current Status and Prospects of Immunotherapy for Gynecologic Melanoma. Journal of Personalized Medicine, 2021, 11, 403.	2.5	4
121	Transcription Factor Homeobox D9 Drives the Malignant Phenotype of HPV18-Positive Cervical Cancer Cells via Binding to the Viral Early Promoter. Cancers, 2021, 13, 4613.	3.7	4
122	The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG. Journal of Gynecologic Oncology, 2020, 31, e94.	2.2	4
123	Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. Journal of Gynecologic Oncology, 2021, 33,	2.2	4
124	Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer. Pharmaceuticals, 2022, 15, 124.	3.8	4
125	Hereditary Endometrial Cancer: Lynch Syndrome. Current Obstetrics and Gynecology Reports, 2013, 2, 11-18.	0.8	3
126	Enhanced fucosylation of GA1 in the digestive tracts of X-ray-irradiated mice. Glycoconjugate Journal, 2017. 34. 163-169.	2.7	3

#	Article	IF	CITATIONS
127	Population-based cohort study assessing the efficacy of cervical cytology (Pap smear) and human papillomavirus (HPV) testing as modalities for cervical cancer screening. Japanese Journal of Clinical Oncology, 2018, 48, 495-498.	1.3	3
128	Characterization of a novel glycolipid with a difucosylated H-antigen in human blood group O erythrocytes with monoclonal antibody HMMC-1 and its detection in human uterine cervical carcinoma tissues. Glycoconjugate Journal, 2019, 36, 219-226.	2.7	3
129	A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer. International Journal of Clinical Oncology, 2021, 26, 1977-1985.	2.2	3
130	Surveillance of radical hysterectomy for early-stage cervical cancer in the early experienced period of minimally invasive surgery in Japan. International Journal of Clinical Oncology, 2021, 26, 2318-2330.	2.2	3
131	A Possible Inhibitory Role of Sialic Acid on MUC1 in Peritoneal Dissemination of Clear Cell-Type Ovarian Cancer Cells. Molecules, 2021, 26, 5962.	3.8	3
132	Blood-direct InvaderPlus [®] as a new method for genetic testing. Personalized Medicine, 2012, 9, 657-663.	1.5	2
133	Absence of lactobacilli containing glycolipids with the Â-galactose epitope and the enhanced fucosylation of a receptor glycolipid GA1 in the digestive tracts of immune-deficient scid mice. Journal of Biochemistry, 2015, 158, 73-82.	1.7	2
134	Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment. Journal of Obstetrics and Gynaecology Research, 2015, 41, 1598-1606.	1.3	2
135	Atypical endometrial hyperplasia diagnosed by hysteroscopic photodynamic diagnosis using 5-aminolevulinic acid. Photodiagnosis and Photodynamic Therapy, 2019, 26, 45-47.	2.6	2
136	Understanding of the position of patients with <scp>Mayer–Rokitansky–Küster–Hauser</scp> syndrome revealed by uterus transplantation research in Japan. Journal of Obstetrics and Gynaecology Research, 2021, 47, 2246-2246.	1.3	2
137	Incidence of germline variants in Lynch syndrome-related genes among Japanese endometrial cancer patients aged 40Âyears or younger. International Journal of Clinical Oncology, 2021, 26, 1767-1774.	2.2	2
138	Keio Uterus Transplantation Research: From Basic Research toward Future Clinical Application. Keio Journal of Medicine, 2022, 71, 33-43.	1.1	2
139	Living donor surgery in uterus transplantation: A delicate hysterectomy technique in gynecological surgery. Journal of Obstetrics and Gynaecology Research, 2022, 48, 2652-2653.	1.3	2
140	Phenotypic Alteration of Carbohydrate Antigens in Gynecological Malignancy Acta Histochemica Et Cytochemica, 1995, 28, 197-201.	1.6	1
141	Experimental techniques for the development of a uterus transplantation model in cynomolgus macaques. Journal of Obstetrics and Gynaecology Research, 2020, 46, 2251-2260.	1.3	1
142	A retrospective study for investigating the outcomes of endometrial cancer treated with radiotherapy. International Journal of Gynecology and Obstetrics, 2022, 156, 262-269.	2.3	1
143	The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer. International Journal of Clinical Oncology, 2021, 26, 2123-2129.	2.2	1
144	Optimal debulking surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese Gynecologic Oncology Group Journal of Clinical Oncology, 2015, 33, 5591-5591.	1.6	1

#	Article	IF	CITATIONS
145	Hysteroscopic treatment assisted by photodynamic diagnosis for atypical polypoid adenomyoma: A report of two cases. Photodiagnosis and Photodynamic Therapy, 2021, 36, 102583.	2.6	1
146	Phenotypic alterations of a carbohydrate antigen, blood group A type 3 chain, in neoplastic transformation of uterine cervix. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 1994, 27, 312-314.	1.8	0
147	Two Soluble Forms of .BETA.1,4-Galactosyltransferase Released from Ovarian Cancer Cells and from COS-1 Cells Transfected with its cDNA Acta Histochemica Et Cytochemica, 1999, 32, 209-214.	1.6	0
148	Subcellular Localization of Galactosyltransferase Associated with Tumors in Endometrial and Ovarian Cancer Cells Acta Histochemica Et Cytochemica, 2003, 36, 205-214.	1.6	0
149	Abstract of Poster Presentation. Human Cell, 2005, 18, 43-65.	2.7	0
150	Current progress of uterus transplantation in Asia. Journal of Obstetrics and Gynaecology Research, 2020, 46, 2456-2456.	1.3	0
151	Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy. Japanese Journal of Clinical Oncology, 2022, 52, 128-133.	1.3	0
152	Uterus Transplantation and Surrogacy in Japan: a Country in which Surrogacy is Prohibited. Academic Collaborations for Sick Children, 2011, 4, 21-27.	0.2	0
153	Gene scoring model to predict recurrence in low- and intermediate-risk uterine endometrial cancer: Establishment of uterine print Journal of Clinical Oncology, 2013, 31, 5590-5590.	1.6	0
154	A case of "retained products of conception" treated with hysteroscopic surgery occurring after cesarean delivery in a patient who underwent fertility-preserving therapy for endometrial cancer. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2020, 36, 317-321.	0.0	0
155	Risk-Reducing Salpingo-oophorectomy (RRSO). , 2021, , 183-191.		0
156	Clinical Usefulness of Endometrial Cytology in Determining the Therapeutic Effect of Fertility Preserving Therapy. Acta Cytologica, 2022, 66, 106-113.	1.3	0